1-es típusú cukorbetegség: vizsgálatok itt: Japán
6 trials · From ClinicalTrials.gov, checked 2026. november 12.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Where
- Chūōku, Ichinomiya-shi, Izunokuni-shi, Kamakura-shi, Kawagoe-shi, Kitakyushu-shi, Kyoto, Mito, Nishinomiya-shi, Ōmihachiman, Yokohama
- Életkor
- 18 év and over
- People
- 500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07776509 · EU 2025-523295-23-00 - 3. fázisTaking peopleA Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
- Where
- Abeno, Iruma, Kawasaki, Kofu, Kōriyama, Kumamoto, Nagano, Naka, Niigata
- Életkor
- 1 év to 35 év
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222137 · EU 2025-521797-34-00 - 3. fázisTaking peopleA Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
- Where
- Ichikawa, Iruma, Moriyama, Osaka, Sendai, Shizuoka
- Életkor
- 1 év to 35 év
- People
- 300 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07222332 · EU 2025-522170-36-00 - 3. fázisTaking peopleA Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Where
- Chūōku, Fukuoka, Hachioji-shi, Osaka, Shibuya-ku, Takatsuki-shi
- Életkor
- 18 év and over
- People
- 2500 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07784725 · EU 2025-523379-41-00 - 3. fázisTaking peopleA Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes
- Where
- Azumino, Chiba, Fukuoka, Iruma, Kobe, Koshigaya, Kyoto, Moriyama, Nagoya, Nara, Niigata, Osaka, Sapporo, Shimajiri, Shizuoka, Tokyo, Yokohama
- Életkor
- 1 év to 25 év
- People
- 723 worldwide
- Run by
- Sanofi
See details and how to joinNCT07088068 - No phaseTaking peopleGeneral Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus
- Where
- Aichi, Aomori, Chiba, Chitose, Hokkaido, Ehime, Fukuoka, Gifu, Gunma, Hiroshima, Hokkaido, Hyōgo, Hyogogoken, Ibaraki, Kagawa, Kagoshima-shi, Kagoshima, Kanagawa, Kisarazu-shi, Chiba, Koriyama-shi, Fukushima, Kumamoto, Kumamoto-shi, Kumamoto, Kyoto, Kyoto-shi, Kyoto, Mie, Mitaka-shi, Tokyo, Miyazaki, Muroran-shi, Hokkaido, Nagano, Nagasaki, Niigata, Numakunai, Ōita, Oita-shi, Oita,, Okayama, Okinawa, Osaka, Saga, Saitama, Sendai-shi, Miyagi, Shiga, Shimane, Shizuoka, Tamana-shi, Kumamoto, Tochigi, Tokushima, Tokyo, Tottori, Wakayama, Yamagata, Yamaguchi, Yamato-shi, Kanagawa
- People
- 630
- Run by
- Novo Nordisk A/S
See details and how to joinNCT06807190